You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Andtbacka RH, Collichio FA, Amatruda T, et al
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Journal for ImmunoTherapy of Cancer 2014;2:P263. doi: 10.1186/2051-1426-2-S3-P263